2023-503891-26-00CompletedPhase 1
Investigation of safety, tolerability and pharmacokinetics of multiple doses of NNC0113‑6856 in healthy participants, including a subset of healthy Japanese participants
Source: EU CTIS (euclinicaltrials.eu) · Last updated 25 Apr 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 170 (actual)
- First submitted
- 13 Jun 2023
- Start date
- 29 Sept 2023
- Lead sponsor
- Novo Nordisk A/S
- EU CT number
- 2023-503891-26-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 170
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PROFIL Institut fuer Stoffwechselforschung GmbH | Neuss | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.